However, administration for 4 weeks of Fc-apelin-13 (apelin-13 fused with IgG Fc fragment) in obese mice significantly improves glucose tolerance, stroke volume, and cardiac output, while it decreases cardiac and hepatic fibrosis; but it does not affect food intake and body weight (120). This evidence concerns the gene APLN and Hepatic fibrosis.